475 related articles for article (PubMed ID: 18707605)
1. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.
Kim DH; Kumar D; Messner HA; Minden M; Gupta V; Kuruvilla J; Chae YS; Sohn SK; Lipton JH
Clin Transplant; 2008; 22(6):770-9. PubMed ID: 18707605
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
Kim DH; Messner H; Minden M; Gupta V; Kuruvilla J; Wright J; Lipton J
Transpl Infect Dis; 2008 Apr; 10(2):90-8. PubMed ID: 17605742
[TBL] [Abstract][Full Text] [Related]
3. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
4. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of varicella zoster virus infection following allogeneic stem cell transplants].
Doki N; Hoshino T; Irisawa H; Sakura T; Miyawaki S
Rinsho Ketsueki; 2004 Oct; 45(10):1090-4. PubMed ID: 15553042
[TBL] [Abstract][Full Text] [Related]
6. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
[TBL] [Abstract][Full Text] [Related]
8. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia.
Sempere A; Sanz GF; Senent L; de la Rubia J; Jarque I; López F; Arilla MJ; Guinot M; Martín G; Martínez J
Bone Marrow Transplant; 1992 Dec; 10(6):495-8. PubMed ID: 1362686
[TBL] [Abstract][Full Text] [Related]
9. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
[TBL] [Abstract][Full Text] [Related]
10. Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue.
Bilgrami S; Chakraborty NG; Rodriguez-Pinero F; Khan AM; Feingold JM; Bona RD; Edwards RL; Dorsky D; Clive J; Mukherji B; Tutschka PJ
Bone Marrow Transplant; 1999 Mar; 23(5):469-74. PubMed ID: 10100561
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.
Onozawa M; Hashino S; Haseyama Y; Hirayama Y; Iizuka S; Ishida T; Kaneda M; Kobayashi H; Kobayashi R; Koda K; Kurosawa M; Masauji N; Matsunaga T; Mori A; Mukai M; Nishio M; Noto S; Ota S; Sakai H; Suzuki N; Takahashi T; Tanaka J; Torimoto Y; Yoshida M; Fukuhara T
Biol Blood Marrow Transplant; 2009 Jun; 15(6):724-9. PubMed ID: 19450757
[TBL] [Abstract][Full Text] [Related]
12. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
14. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications.
Han CS; Miller W; Haake R; Weisdorf D
Bone Marrow Transplant; 1994 Mar; 13(3):277-83. PubMed ID: 8199570
[TBL] [Abstract][Full Text] [Related]
15. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
Steer CB; Szer J; Sasadeusz J; Matthews JP; Beresford JA; Grigg A
Bone Marrow Transplant; 2000 Mar; 25(6):657-64. PubMed ID: 10734301
[TBL] [Abstract][Full Text] [Related]
16. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
Verma A; Devine S; Morrow M; Chen YH; Mihalov M; Peace D; Stock W; Pursell K; Wickrema A; Yassine M; Jessop E; van Besien K
Bone Marrow Transplant; 2003 May; 31(9):813-6. PubMed ID: 12732890
[TBL] [Abstract][Full Text] [Related]
17. Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.
Han SB; Kim SK; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH
Medicine (Baltimore); 2017 Apr; 96(14):e6546. PubMed ID: 28383421
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of quantitative varicella-zoster virus (VZV) DNA detection in plasma after stem cell transplantation.
Kalpoe JS; Kroes AC; Verkerk S; Claas EC; Barge RM; Beersma MF
Bone Marrow Transplant; 2006 Jul; 38(1):41-6. PubMed ID: 16715108
[TBL] [Abstract][Full Text] [Related]
19. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Wada-Shimosato Y; Tanoshima R; Hiratoko K; Takeuchi M; Tsujimoto SI; Shiba N; Ito S; Yamanaka T; Ito S
Transpl Infect Dis; 2019 Jun; 21(3):e13061. PubMed ID: 30756465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
